MedTrace Logo

Phase III Study of ASP2151 in Herpes Simplex Patients

NCT01959295 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2024-10-09

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.

Conditions

  • Herpes Simplex

Interventions

DRUG

ASP2151

200 mg once daily

DRUG

ASP2151 placebo

once daily

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-04-30
Completion
2015-04-27

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959295 on ClinicalTrials.gov